Scleroderma is a condition of variable phenotype characterised by fibrosis of the skin and internal organs. There is a range of disease-specific autoantibodies found in the sera of patients. The aims of this study were to: (1) investigate the role of the MHC and particularly HLA-DP in the production of autoantibodies; (2) investigate clinical associations with autoantibodies. We have performed HLA class II typing using PCR with sequence-specific primers on DNA samples from 202 scleroderma patients and 307 UK control subjects. All patients had well defined clinical phenotypes. Sera from patients were examined for the presence of disease specific autoantibodies in particular the anti-topoisomerase autoantibody (ATA), the anti-centromere autoantibody (ACA) and the anti-RNA polymerase autoantibody (ARA). There was a striking association between HLA-DPB1*1301 and ATA (P corr = 0.0001). In addition, ATA was associated with HLA-DRB1*11 and the anticentromere autoantibody (ACA) with HLA-DRB1*04, HLA-DRB1*08 (P = 0.001) and HLA-DQB1 alleles with a glycine residue at position 26. Very strong associations were detected between clinical phenotypes and autoantibodies. ATA was associated with pulmonary fibrosis (P = 0.00002), anti-RNA polymerase autoantibody (ARA) with renal involvement (P = 0.0000006) and diffuse skin disease (P = 0.00001), and ACA with limited skin involvement (P = 0.00002) and protection against pulmonary fibrosis (P = 0.0000003). We have identified a significant association between the ATA and HLA-DPB1*1301 which may provide an insight into how this autoantibody is formed. Patient clinical characteristics depend on the autoantibodies they carry. Genes and Immunity (2001) 2, 76-81.
Introduction
Systemic sclerosis (scleroderma) is a condition characterised by fibrosis of the skin and internal organs. Clinically it is highly heterogeneous and it has been suggested that the term 'systemic sclerosis' includes several different diseases sharing a common dermatological phenotype. The clinical outcome is determined by the pattern of internal organ involvement. Pulmonary fibrosis, scleroderma renal crisis and pulmonary hypertension all have high mortality. One prominent feature of the condition is the presence of serum antinuclear antibodies, which are estimated to be present in up to 90% of scleroderma patients. 1 Although a pathogenic role has yet to be established for any scleroderma-specific autoantibody they appear to be associated with different clinical subsets of the disease. 2 The anti-topoisomerase antoantibody (ATA) has been found to be associated with pulmonary fibrosis 3 while the anti-centromere autoantibody (ACA) has been linked to limited disease. 4 Autoantibodies against RNA polymerase (ARA) I and III are specific for scleroderma and are associated with diffuse disease with a high incidence of heart and kidney involvement. 5 Rarer scleroderma specific autoantibodies are anti-Ku, anti-U3-RNP (fibrillarin), anti-U1-RNP, anti-ThRNP and anti-PM-Scl, which is particularly associated with scleroderma with polymyositis, overlap. 6 Anti-U3-RNP autoantibodies have been linked to a high incidence of pulmonary hypertension. 7 We have previously shown the mutual exclusivity of scleroderma specific autoantibodies; it is rare that a patient will carry more than one of these autoantibodies. 8 The mechanism of production of these autoantibodies and how this relates to the development of the clinical syndromes with which they are associated is unknown, although MHC class II HLA molecules are likely to play a role. Autoantibody formation is an antigen driven process requiring presentation of processed antigen by class II HLA MHC molecules to helper T cells resulting in activation, proliferation, and induction of an antigen-specific immune response. 9 There have been a variety of studies that have shown associations between HLA-DR and -DQ alleles and autoantibody profile in scleroderma. Several class II MHC associations have been identified for the ATA autoantibody in different ethnic populations including HLA-DR15 (DRB1*1501, *1502), -DR11 (DRB1*1101, *1103, *1104) and -DR7 (DRB1*701). [10] [11] [12] [13] Increased frequencies of HLA-DR1, HLA-DR4 and HLA-DR8 have been reported to be associated with ACA.
14 However, others have reported the primary association to be with the HLA-DQB locus with a polar glycine or tyrosine residue at position 26 of the beta chain of the HLA-DQ. 15 In the largest study to date of patients carrying the PM-Scl autoantibody, all subjects were positive for HLA-DR3. 6 For other autoantibodies in systemic sclerosis, HLA associations are either absent (ARA) or less clear.
Evidence for a role for HLA-DP in scleroderma is less clear. Early studies concluded that there is no primary association between HLA-DP and scleroderma. 16 This is supported by the work of Kuwana et al 10 in which the use of blocking antibodies to HLA-DR, HLA-DQ and HLA-DP showed that the response to topoisomerase is dependent on HLA-DR and to a lesser extent HLA-DQ. Other studies have shown associations between subgroups of scleroderma and HLA-DP alleles. 17, 18 Thus, although associations between class II HLA antigens and autoantibodies have been investigated in the past, results are not concordant. This lack of concordance may in part be due to differences in susceptibility alleles between ethnic groups, heterogeneity of subset of disease or, alternatively, the strong linkage disequilibrium existing between class II alleles may make identification of primary associations complex.
By using PCR based HLA typing methods with sequence-specific primers (PCR-SSP) we aimed to accurately HLA type DNA from well-characterised Caucasian patients and controls for the three HLA class II molecules, HLA-DR, HLA-DQ and HLA-DP. Clinical and immunological phenotypes were determined as accurately as possible by two clinical consultants so that associations would not be obscured.
Results

Patient characteristics
Two hundred and two UK Caucasoid patients with scleroderma were studied. Their immunological and Table 1 Association between clinical phenotypes and autoantibody profiles in scleroderma patients clinical phenotypes are shown in Table 1 . There was almost total mutual exclusivity between sclerodermaspecific autoantibodies: a single patient was positive for both ACA and ATA.
Autoantibody associations with clinical subgroups
Strong associations between autoantibodies and disease phenotypes were found. Table 1 shows these associations with P values obtained using the Chi-squared test. The strongest association found was between ACA and the lack of fibrosing alveolitis (P = 0.0000003). Patients in all other autoantibody groups except those positive for the anti-U3-RNP antibody suffer from fibrosing alveolitis. However, the presence of ACA is strongly protective against this complication of scleroderma. The association between limited disease and the presence of ACA was also confirmed (P = 0.00002).
Pulmonary fibrosis was significantly associated with ATA. Of the 54 patients positive for ATA, 48 had evidence of pulmonary fibrosis (P = 0.00002). However, though showing a high degree of specificity for pulmonary fibrosis, ATA lacks sensitivity. Of 120 patients identified as having pulmonary fibrosis, only 48 (40%) also had ATA.
ARA was found to be a marker with high sensitivity for renal disease. Thirteen of 15 patients (87%) with renal involvement were also positive for ARA (P = 0.0000006). However there were a further 29 patients positive for ARA but negative for renal disease. In addition, there was a highly significant association between ARA and diffuse skin involvement (P = 0.00001). Table 2 shows the distribution of HLA class II phenotypes in patients according to their autoantibody profile. Significant associations were found between autoantibodies and different HLA class II alleles.
HLA associations with autoantibodies
Anti-topoisomerase:
The most striking finding of this study was a highly significant increase in the frequency of the HLA-DPB1*1301 allele in the ATA positive group. Nineteen of the 54 patients who carried the ATA were positive for HLA-DPB1*1301. This is highly significant when compared to patients negative for ATA (P corr = 0.0001). The previously reported association between ATA and DRB1* 11 including 1101-1121 was confirmed. Of 19 patients positive for both HLA-DPB1*1301 and ATA, 16 (84%) had limited disease, 17 (89%) fibrosing alveolitis and 14 (74%) had both fibrosing alveolitis and limited skin involvement. When this was compared with ATA-positive patients lacking HLA DPB1*1301, 13/35 (37%) had both limited disease and fibrosing alveolitis.
Twenty-one of the 54 ATA-positive patients were positive for HLA-DRB1*11. This was statistically significant when compared with ATA-negative patients (P = 0.00006). Associations with HLA-DRB1*15 and HLA-DRB1*07 were not confirmed. Although 19/54 patients positive for ATA were also positive for DRB1*15 and 12/54 patients were positive for both ATA and HLA-DRB1*07, neither association reached statistical significance. No associations were observed between the ATA autoantibody and any HLA-DQB1 allele. Previous work has suggested that HLA-DR and to a lesser extent HLA-DQ are the important alleles in the formation of ATA. However, the findings here suggest an important role for HLA-DPB1*1301.
Anti-centromere autoantibody: An association was found between HLA-DRB1*04 and the presence of the ACA. Twenty-seven of 53 (51%) patients with ACA were HLA-DRB1*4 positive compared with 39 out of 149 (26%) who were ACA-negative (P = 0.001). Eleven of 53 (21%) ACApositive patients had the HLA-DRB1*08 which again was significantly increased compared to ACA-negative patients (P = 0.001).
In previous reports, ACA positivity has been associated with HLA-DRB1*01. No significant differences were found in the present study in the distribution of this allele when comparing ACA-positive and -negative patients.
It is possible that the relationships observed between specific HLA alleles and ACA positivity are due to their being in linkage disequilibrium with other alleles. HLA-DQB1*04 is in linkage disequilibrium with HLA-DRB1* 08. HLA-DQB1*04 was found in 11/53 ACA-positive patients. HLA-DRB1*01 and HLA-DRB1*14 are in linkage disequilibrium with HLA-DQB1*05. However, although present in 22/53 ACA-positive patients, this allele is not increased significantly, which is consistent with the failure to identify a significant association with HLA-DRB1* 01. It is notable that both HLA-DQB1*04 and HLA-DQB1* 05 have the amino acid glycine at position 26. This amino acid at position 26 of HLA-DQB1 was found more frequently in ACA-positive patients than in the ACA negative group (31/53 of the ACA-positive group compared with 42/149 in the ACA-negative group, P = 0.0008).
Anti-RNA polymerase group: Weak associations were found between ARA positivity and DQB1*02 which is in tight linkage disequilibrium with HLA-DRB1*03. However this allele was also not significantly associated with ARA positivity.
PM-SCL:
As previously reported the presence of the PM-SCL autoantibody was associated with HLA-DRB1*03 with five of six patients being positive for this allele.
Discussion
The most striking finding in this study was the strong association between HLA-DPB1*1301 and the presence of ATA (P uncorr = 0.000003, P corr = 0.0001). This contrasts with some negative studies and provides stronger associations than previous positive studies. 17, [19] [20] [21] [22] We conclude that HLA-DP may be important in the production of this autoantibody. It is probable that the advance in DP typing and ATA detection methodologies are the reasons for these differences. However a role for HLA-DP runs contrary to the findings of Kuwana et al 10, 23 who found anti-HLA-DP antibodies did not affect topoisomeraseinduced T cell proliferation in ATA-positive patients while anti HLA-DR, and to a lesser extent anti HLA-DQ, antibodies inhibited proliferation. It is possible that HLA-79 DP alleles are not the restricting elements of the topo Iinduced T cell response. Alternatively, a possible explanation for this discrepancy is that HLA-DPB1*1301 is important in some patients while different alleles play the significant role in other populations. In the study of Kuwana et al 10 none of the patients in whom HLA-DP blocking antibodies were tested were HLA-DPB1*1301 positive.
We have a number of lines of evidence that suggest that the subset of patients who are HLA-DPB1*1301/ ATA positive form a unique subgroup within the scleroderma population. Firstly, the HLA-DPB1*1301/ATApositive group have less severe skin involvement in comparison to the HLA-DPB1*1301-negative/ATA-positive group although the frequency of pulmonary fibrosis is equivalent in the two groups. Thus, the presence of HLA-DPB1*1301 protects against skin disease but not against pulmonary fibrosis in ATA-positive subjects. Of 19 patients positive for both HLA-DPRB1*1301 and ATA, 16 (84%) had limited disease, 17 (89%) fibrosing alveolitis and 14 (74%) had both fibrosing alveolitis and limited skin involvement. When this is compared with ATApositive patients lacking HLA DPB1*1301, 13/35 (37%) have both limited disease and fibrosing alveolitis. In our patient group the HLA-DPB1*1301/ATA-positive DPB1* 1301/ATA-positive sub-population appears to have a distinct clinical phenotype compared with other ATApositive populations. Previous work has suggested that HLA-DR, and to a lesser extent HLA-DQ, are the important alleles in the formation of ATA. However, the findings here suggest an important role for HLA-DPB1* 1301.
In this regard it is striking to note that HLA-DPB1*1301 has an unusual sequence among HLA-DPB1 alleles. It is one of a group with a glutamate residue at position 69 of the beta chain instead of the more common lysine. Glutamate at position 69 results in three consecutive glutamate residues instead of two acidic glutamates on either side of a basic lysine or (very rarely) an arginine. In addition, HLA-DPB1*1301 has the sequence AAE (alanine, alanine, glutamate) at positions 55 to 57. The combination of this motif with glutamate 69 is shared only with extremely rare alleles (HLA-DPB1*3301, 5501, 5801 and 7101). All other alleles have a second triplet of acidic residues at positions 55-57 or rarely two acidic and one neutral amino acid: either DEE (asparate, glutamate, glutamate), DED (aspartate, glutamate, aspartate) or occasionally EAE (glutamate, alanine, glutamate). Thus HLA-DPB1*1301 is unusual in having only a single triplet of acidic residues in this region which is important for antigen binding.
A single triplet of acidic amino acids is also found within the binding region of other alleles noted in previous publications to be associated with ATA. The HLA-DRB1*1101-1122 alleles which have been found to be associated with ATA 10 have a triplet of amino acids, DEE (aspartate, glutamate, glutamate) at positions 57 to 59 of the polypeptide chain. HLA-DRB1*15 which has also been associated with ATA 10 lacks a triplet of acidic amino acids. However, this allele is in strong linkage disequilibrium with HLA-DRB5, suggesting that these alleles are also involved in production of ATA. We hypothesise that other alleles that contain this motif may also be associated with ATA. Of interest, HLA-DRB1*1602 is in strong linkage disequilibrium with HLA-DRB5. The Choctaw
Genes and Immunity population of Oklahoma have an increased incidence of scleroderma and it has been found that the strongest risk factor for the condition is the haplotype B35, Cw4, DRB1* 1602 DQA1*0501 and DQB*0301. 24 In a Japanese population, HLA-DRB1*1502 has been shown to be associated with scleroderma and ATA. 25 The significant association found between ATA and HLA-DPB1*1301 may not relate directly to its amino acid sequence and structure but may result from linkage disequilibrium with another allele within the HLA region. The results presented here do not support this hypothesis as linkage disequilibrium was not found between HLA-DPB1*1301 and either HLA-DRB1 or HLA-DQB. However, linkage disequilibrium could exist with other genes on the same chromosome possibly outside the HLA region which have not been investigated here.
Another possibility is that HLA-DPB1*1301 differs from other HLA-DPB1 alleles in ways other than amino acid sequence. It has been reported that levels of expression of HLA-DP on immunologically active cells are low. 26, 27 It is possible that upstream sequences in HLA-DPB1*1301 ensure it is transcribed at an increased level compared with other HLA-DPB1 alleles giving it the ability to play a role in ATA production where other alleles of similar sequence take no active part.
A second aim of this study was to see if there were associations between HLA-DPB1 alleles and any other autoantibodies, which would allow the mechanism involved in their formation to be elucidated. No new associations were detected between the autoantibody groups studied and HLA-DPB1 alleles. However, previously noted associations with HLA-DR and HLA-DQ were confirmed with increased significance. A polar glycine or tyrosine residue at position 26 in HLA-DQB1 has been reported to be present in 100% of American patients positive for ACA. 15 Our study confirmed a significant increase in HLA-DQB1 residues with glycine 26 in the ACA-positive patients (P = 0.0008). However, this was present in only 31/53 ACA-positive patients, thus it cannot be the whole explanation for the formation of ACA. The lack of clear HLA associations in this group may be because the ACA autoantibodies detected are heterogeneous and there are distinct subgroups within the cohort as a whole, each being associated with different HLA alleles.
The associations between autoantibody and clinical subset were also very strong in this study, again probably because of the rigorous patient definition. ATA autoantibody is associated with pulmonary fibrosis, ACA with limited disease and ARA with diffuse disease and renal involvement. The presence of the ACA autoantibody provides marked protection from pulmonary fibrosis, an association not previously described. Associations between clinical characteristics and HLA phenotypes were also detected but these are weaker than those between clinical characteristics and autoantibodies and appear to be secondary to these associations.
In summary, this study has extended previous data suggesting an association between HLA-DPB1*1301 and the ATA autoantibody. Our data have shown this to be more highly significant than previous studies, which we attribute to stringent clinical, autoantibody and HLA phenotyping. Mechanisms for the role of this allele are suggested. The study has also confirmed and strengthened associations between scleroderma-specific autoanti-bodies and clinical phenotypes and has noted a new association between the ACA autoantibody and protection from pulmonary fibrosis. In addition, previously reported associations between autoantibodies and HLA-DR and HLA-DQ alleles have been confirmed in our phenotypically well-defined population.
Patients and methods
Patients
Two hundred and two UK Caucasian patients attending the Royal Free and Royal Brompton Hospitals were studied. Patients come from both the local area and the rest of the UK. All patients fulfilled the American College of Rheumatology preliminary criteria for scleroderma. 28 
Clinical data
Patients were classified into limited and diffuse groups depending on the extent of skin involvement. Limited disease was defined as skin involvement restricted to the extremities and face. Those with diffuse disease showed skin involvement extending proximal to the elbows and towards the trunk.
Pulmonary fibrosis was diagnosed in the majority of patients by high resolution computed tomography (HRCT) and confirmed in 47 by open lung biopsy. A small proportion of patients had not undergone HRCT. In these cases pulmonary fibrosis was diagnosed based on a compatible chest radiograph and a restrictive deficit on pulmonary function testing. Those without pulmonary fibrosis all had a normal chest radiograph or CT scan. All patients classified as having renal disease had a diagnostic renal biopsy.
Control subjects
Control subjects consisted of 307 UK Caucasian cadaver organ donors seen at the Oxford Transplant Centre, Churchill Hospital. These were comparable with the patient group as they too were drawn from the local area and to a lesser extent the whole of the UK and had a similar age range to the patients. The representative nature of this control set for UK Caucasoids has been repeatedly demonstrated in multiple HLA genotyping studies. 29, 30 Autoantibody analysis Sera from all patients were assessed for the presence of antinuclear antibodies and extractable nuclear antigens. ACA and anti-U3-RNP autoantibodies were identified by the indirect immunofluorescence pattern on Hep-2 cell substrate (Bion Inc, Park Ridge, IL, USA) with rabbit antihuman polyvalent fluoroscein isothiocyanate conjugate (F0200, DAKO, Ely, Cambs, UK) and viewed at × 400 magnification on a fluorescent microscope. 31 ATA and anti-PM-Scl antibodies were identified by counterimmunoelectrophoresis using a soluble rabbit thymus extract and antisera of confirmed specificity. 32 ARA antibodies were detected by immunoprecipitation of antigen from a radiolabelled HeLa cell extract using patient antibodies bound to protein A sepharose and visualised by autoradiography following separation on 8% polyacrylamide gels. 20, 33 The presence of other autoantibodies, with the exception of anti-centromere, was also confirmed by this method.
DNA extraction
Genomic DNA was isolated from peripheral blood lymphocytes using a modified version of the salting-out method.
34
HLA genotyping HLA class II genotyping was carried out by PCR with sequence specific primers. HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5 and HLA-DQB1 were typed using the phototype method as previously described. 35 HLA-DPB1 typing was carried out using a modified version of our 96 reaction method for comprehensive HLA-DPB and HLA-DPA typing. 36 Twenty-four primer mixes were used allowing identification of the 20 most common HLA-DPB1 alleles in most combinations. The only alleles which cannot be distinguished are HLA-DPB1*0801 and HLA-DPRB1*1601 which differ at a single amino acid residue. For the purposes of this paper these are considered together.
Statistical analysis
Associations were investigated between: (1) clinical features; (2) autoantibodies; (3) HLA class II alleles. Differences between groups were tested using the Chi-squared test. Where associations had previously been reported, no correction was made to the P value. New associations were corrected for the number of comparisons made using the formula P corr = 1 − (1 − P) n where n is the number of comparisons made and P the uncorrected P value.
